Medlab has already developed two cannabis-based medicines, NanaBis™ and NanaBidial™.
Showing 25 of 177
The trial is designed to meet the Therapeutic Goods Administration's requirements for expedited drug approval.
Conditions have been met for three agreements outlined in a binding term sheet in May 2018.
Shares in the company have doubled to 19.5 cents over the past 12 months.
Regular material revenue is expected to commence during this December half.
The company's lead drug candidate is a cannabis-derived canine pain medication.
The SPP demonstrates that the company is willing to reward loyal shareholders.
The company has multiple medical cannabis research partners across the world.
The company’s shares are trading 28% higher intra-day, at 3.2 cents.
The company now has complete end-to-end growing and manufacturing facilities.
Shares in the company were up 163% to 7.9 cents in the early afternoon.
The companies intend to develop and produce CBD-based and THC-based products.
Medlab has approval to supply NanaBis™ under the TGA's Special Access Scheme.
Newly established relationship in Canda provides THC with access to additional cannabis strains.
An $8 million share purchase plan (SPP) will follow the placement.
The company has entered into a research services agreement Eurofins Animal Health Pty Ltd.
Negotiations between the parties involved have progressed well.
A new agreement will see the companies share medicinal cannabis product and knowledge.
The company has entered a research agreement which includes funding under the Kick-Start initiative for SMEs.
Katy Williams Day is the new product and regulatory affairs manager for THC Pharma.
Approved Australian patients will be able to access products under the government’s Special Access Scheme.
The company has appointed Canadian Luke Pigeau and entered a research and development agreement with Jade Cannabis.
Rhinomed is a medical technology company with a patented nasal technology platform.
CannPal has identified an opportunity in the medical cannabis and health markets.
The crop is grown in DayaCann’s 30-hectare facility in the south of Santiago, Chile.